Tvardi Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -6,606 | -6,804 | -7,251 | -5,503 |
EBIT | -6,629 | -7,275 | -5,527 | |
Net Income | -6,457 | -6,804 | -7,275 | -5,527 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -9,228 | -5,859 | -5,685 | -4,257 |
Cash | 15,765 | 19,851 | 20,734 | 21,418 |
Basic Shares | 9,381 | 9,381 | 9,380 | 9,377 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $7,137 | $20,968 | $41,867 |
Gross Profit | -95 | 6,325 | 14,535 | 34,353 |
EBITDA | -18,119 | -62,600 | -117,650 | -83,804 |
EBIT | -18,214 | -62,792 | -117,909 | -85,474 |
Net Income | -18,214 | -70,867 | -118,513 | -85,474 |
Net Change In Cash | 0 | 7,137 | 20,968 | 41,867 |
Free Cash Flow | -23,499 | -61,963 | -94,453 | -17,916 |
Cash | 20,734 | 37,903 | 22,919 | 21,489 |
Basic Shares | 7,783 | 1,520 | 9,355 | 9,355 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.69 |
2026-03-31 | -$0.73 |
2025-12-31 | -$0.78 |
2025-09-30 | -$0.59 |